Current evidence on TNX-102 SL (cyclobenzaprine HCl sublingual) for fibromyalgia: strengths, limitations, and emerging hypotheses
Clinical Rheumatology · 2026-02 · 45 (2) · 1609-1611
DOI: 10.1007/s10067-025-07903-0 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Rheumatology, online erschienen am 03.01.2026. Verfasst von André Pontes-Silva. Beteiligte Einrichtung: Postgraduate Program in Physical Therapy, Department of Physical Therapy, Federal University of Sao Carlos (UFSCar), São Carlos, SP, Brazil. contato.…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Postgraduate Program in Physical Therapy, Department of Physical Therapy, Federal University of Sao Carlos (UFSCar), São Carlos, SP, Brazil. contato.andrepsilva@gmail.com.
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Pontes-Silva, A. (2026). Current evidence on TNX-102 SL (cyclobenzaprine HCl sublingual) for fibromyalgia: strengths, limitations, and emerging hypotheses. Clinical Rheumatology, 45(2), 1609-1611. https://doi.org/10.1007/s10067-025-07903-0
Vancouver
Pontes-Silva A. Current evidence on TNX-102 SL (cyclobenzaprine HCl sublingual) for fibromyalgia: strengths, limitations, and emerging hypotheses. Clinical Rheumatology. 2026;45(2):1609-1611. doi:10.1007/s10067-025-07903-0
BibTeX
@article{PontesSilva2026,
author = {Pontes-Silva, André},
title = {Current evidence on TNX-102 SL (cyclobenzaprine HCl sublingual) for fibromyalgia: strengths, limitations, and emerging hypotheses},
journal = {Clinical Rheumatology},
year = {2026},
volume = {45},
number = {2},
pages = {1609--1611},
doi = {10.1007/s10067-025-07903-0}
}
EUVIMED